Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies

European Journal of Preventive Cardiology

Volumn 23, Issue 1, 2016, Pages 41-49

  Joshi, Parag H ^a   Toth, Peter P ^a,b   Lirette, Seth T ^c   Griswold, Michael E ^c   Massaro, Joseph M ^d   Martin, Seth S ^a   Blaha, Michael J ^a   Kulkarni, Krishnaji R ^e   Khokhar, Arif A ^f   Correa, Adolfo ^c   D'Agustino, Ralph B ^g   Jones, Steven R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d BOSTON UNIVERSITY   (United States)

^e Atherotech Diagnostics Inc   (United States)

^f IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^g Boston University   (United States)

Author keywords

coronary heart disease; High density lipoprotein cholesterol; primary prevention

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVASCULARIZATION; THERAPY; AFRICAN AMERICAN; AGED; BLOOD; CAUCASIAN; CHI SQUARE DISTRIBUTION; CLASSIFICATION; CORONARY DISEASE; DENSITY GRADIENT CENTRIFUGATION; DYSLIPIDEMIAS; INCIDENCE; MASSACHUSETTS; META ANALYSIS; MIDDLE AGED; MISSISSIPPI; MULTIVARIATE ANALYSIS; PARTICLE SIZE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AFRICAN AMERICANS; AGED; BIOMARKERS; CENTRIFUGATION, DENSITY GRADIENT; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CORONARY DISEASE; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MASSACHUSETTS; MIDDLE AGED; MISSISSIPPI; MULTIVARIATE ANALYSIS; PARTICLE SIZE; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84949844226     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314543890     Document Type: Article

References (41)

1. Gofman JW, Young W, Tandy R,. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966; 34: 679-697.
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
3. Hu G, Cui Y, Jousilahti P, et al. Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease. Eur J Prev Cardiol 2013; 20: 89-97.
4. Goff Jr DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (25 Pt B): 2935-2959.
5. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99: 736-743.
6. Cui Y, Watson DJ, Girman CJ, et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol 2009; 104: 829-834.
7. Goldenberg I, Goldbourt U, Boyko V, et al. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol 2006; 97: 466-471.
8. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508.
9. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
10. Group HTC,. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-1291.
11. Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267.
12. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099.
13. Heinecke J,. HDL and cardiovascular-disease risk-time for a new approach? N Engl J Med 2011; 364: 170-171.
14. Shah PK,. Jekyll and Hyde of HDL: A lipoprotein with a split personality. Eur Heart J 2013; 34: 3531-3534.
15. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-135.
16. Movva R, Rader DJ,. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54: 788-800.
17. Vickers KC, Remaley AT,. HDL and cholesterol: Life after the divorce? J Lipid Res 2014; 55: 4-12.
18. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-756.
19. Rosenson RS, Brewer Jr HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905-1919.
20. Heinecke JW,. The protein cargo of HDL: Implications for vascular wall biology and therapeutics. J Clin Lipidol 2010; 4: 371-375.
21. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29: 870-876.
22. Salonen JT, Salonen R, Seppanen K, et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991; 84: 129-139.
23. Lamarche B, Moorjani S, Cantin B, et al. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17: 1098-1105.
24. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-381.
25. Sweetnam PM, Bolton CH, Yarnell JW, et al. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994; 90: 769-774.
26. Superko HR, Pendyala L, Williams PT, et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol 2012; 6: 496-523.
27. Taylor Jr HA, Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: Design and methods of the Jackson Heart Study. Ethn Dis 2005; 15: S6-4-17.
28. Feinleib M, Kannel WB, Garrison RJ, et al. The Framingham Offspring Study. Design and preliminary data. Prev Med 1975; 4: 518-525.
29. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117: 743-753.
30. Kulkarni KR, Marcovina SM, Krauss RM, et al. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J Lipid Res 1997; 38: 2353-2364.
31. Peer N, Steyn K, Lombard C, et al. Alarming rise in prevalence of atherogenic dyslipidaemia in the black population of Cape Town: The Cardiovascular Risk in Black South Africans (CRIBSA) study. Eur J Prev Cardiol. Epub ahead of print 23 July 2013. DOI: 10.1177/2047487313497865.
32. Martin SS, Khokhar AA, May HT, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The lipoprotein investigators collaborative. Eur Heart J. Epub ahead of print 30 June 2014. DOI: 10.1093/eurheartj/ehu264.
33. Vega GL, Clark LT, Tang A, et al. Hepatic lipase activity is lower in African American men than in white American men: Effects of 5' flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res 1998; 39: 228-232.
34. Juo SH, Han Z, Smith JD, et al. Promoter polymorphisms of hepatic lipase gene influence HDL(2) but not HDL(3) in African American men: CARDIA study. J Lipid Res 2001; 42: 258-264.
35. Camont L, Lhomme M, Rached F, et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013; 33: 2715-2723.
36. Shepherd J, Packard CJ, Patsch JR, et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63: 858-867.
37. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-1515.
38. Sorisky A, Ooi TC, Simo IE, et al. Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis 1987; 67: 181-189.
39. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J 2011; 32: 1345-1361.
40. Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
41. Akinkuolie AO, Paynter NP, Padmanabhan L, et al. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes 2014; 7: 55-63.